AlloVir, Inc.

NasdaqCM ALVR

AlloVir, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -950.51%

AlloVir, Inc. EBIT Margin is -950.51% for the Trailing 12 Months (TTM) ending September 30, 2024. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqCM: ALVR

AlloVir, Inc.

CEO	Dr. Diana M. Brainard M.D.
IPO Date	July 30, 2020
Location	United States
Headquarters	1100 Winter Street
Employees	8
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Key trends

Past 5 years